Evidence map›Paper›PMID 31730878›Full record

ArticleThe Journal of allergy and clinical immunology2020

Allergic disease, corticosteroid use, and risk of Hodgkin lymphoma: A United Kingdom nationwide case-control study.

Meena Rafiq, Andrew Hayward, Charlotte Warren-Gash, Spiros Denaxas, Arturo Gonzalez-Izquierdo, Georgios Lyratzopoulos, Sara Thomas

Open access · hybridAbstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Pathogenetic Mechanisms Linking Sarcoidosis to Lymphoma.International journal of molecular sciences · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Meena RafiqInstitute of Health Informatics, UCL, London, United Kingdom. Electronic address: Meena.rafiq@ucl.ac.uk.
Andrew HaywardInstitute of Epidemiology and Health Care, UCL, London, United Kingdom.
Charlotte Warren-GashFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Spiros DenaxasInstitute of Health Informatics, UCL, London, United Kingdom.
Arturo Gonzalez-IzquierdoInstitute of Health Informatics, UCL, London, United Kingdom.
Georgios LyratzopoulosInstitute of Epidemiology and Health Care, UCL, London, United Kingdom.
Sara ThomasFaculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
University College London · GBLondon School of Hygiene & Tropical Medicine · GB

Funding

Cancer Research UK 18180Cancer Research UK C18081/A18180Cancer Research UK C8640/A23385Department of Health IPF-2017-11-011Medical Research Council MR/K006584/1Wellcome Trust 201440/Z/16/Z
6 · The paper itself

Abstract

backgroundImmunodeficiency syndromes (acquired/congenital/iatrogenic) are known to increase Hodgkin lymphoma (HL) risk, but the effects of allergic immune dysregulation and corticosteroids are poorly understood.

objectiveWe sought to assess the risk of HL associated with allergic disease (asthma, eczema, and allergic rhinitis) and corticosteroid use.

methodsWe conducted a case-control study using the United Kingdom Clinical Practice Research Datalink (CPRD) linked to hospital data. Multivariable logistic regression investigated associations between allergic diseases and HL after adjusting for established risk factors. Potential confounding or effect modification by steroid treatment were examined.

resultsOne thousand two hundred thirty-six patients with HL were matched to 7416 control subjects. Immunosuppression was associated with 6-fold greater odds of HL (adjusted odds ratio [aOR], 6.18; 95% CI, 3.04-12.57), with minimal change after adjusting for steroids. Any prior allergic disease or eczema alone was associated with 1.4-fold increased odds of HL (aOR, 1.41 [95% CI, 1.24-1.60] and 1.41 [95% CI, 1.20-1.65], respectively). These associations decreased but remained significant after adjustment for steroids (aOR, 1.25 [95% CI, 1.09-1.43] and 1.27 [95% CI, 1.08-1.49], respectively). There was no effect modification by steroid use. Previous steroid treatment was associated with 1.4-fold greater HL odds (aOR, 1.38; 95% CI, 1.20-1.59).

conclusionsIn addition to established risk factors (immunosuppression and infectious mononucleosis), allergic disease and eczema are risk factors for HL. This association is only partially explained by steroids, which are associated with increased HL risk. These findings add to the growing evidence that immune system malfunction after allergic disease or immunosuppression is central to HL development.

Indexed as

Immunocompromised HostAdolescentAdrenal Cortex HormonesAdultCase-Control StudiesChildChild, PreschoolFemaleHodgkin DiseaseHumansHypersensitivity, ImmediateImmunosuppressive AgentsMaleUnited KingdomYoung AdultAdrenal Cortex HormonesImmunosuppressive AgentsAllergic diseaseallergic rhinitisasthmaatopic dermatitiscorticosteroidseczemaHodgkin lymphomarisk

Identifiers

PMID31730878
PMCPMC7057259
OpenAlexW2987733012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.